Ignite Creation Date:
2024-05-05 @ 5:24 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00444314
Status:
COMPLETED
Last Update Posted:
2011-08-04
First Post:
2007-03-06
Brief Title:
Phase 2 Study of Panzem NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma
Sponsor:
CASI Pharmaceuticals Inc
Organization:
CASI Pharmaceuticals Inc
Study Overview
Official Title:
Phase II Study of 2-Methoxyestradiol Nanocrystal Colloidal Dispersion Alone and in Combination With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma Progressing on Sunitinib Malate
Status:
COMPLETED
Status Verified Date:
2011-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This open-label multicenter Phase 2 trial will assess the anti tumor activity safety and pharmacodynamics of Panzem NCD with or without Sunitinib Malate in patients with metastatic renal cell carcinoma progressing on Sunitinib Malate
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None